Journal article
Thrombolysis by chemically modified coagulation factor Xa
Abstract
Essentials Factor Xa (FXa) acquires cleavage-mediated tissue plasminogen activator (tPA) cofactor activity. Recombinant (r) tPA is the predominant thrombolytic drug, but it may cause systemic side effects. Chemically modified, non-enzymatic FXa was produced (Xai-K), which rapidly lysed thrombi in mice. Unlike rtPA, Xai-K had no systemic fibrinolysis activation markers, indicating improved safety.
SUMMARY: Background Enzymatic thrombolysis …
Authors
Pryzdial ELG; Meixner SC; Talbot K; Eltringham‐Smith LJ; Baylis JR; Lee FMH; Kastrup CJ; Sheffield WP
Journal
Journal of Thrombosis and Haemostasis, Vol. 14, No. 9, pp. 1844–1854
Publisher
Elsevier
Publication Date
9 2016
DOI
10.1111/jth.13402
ISSN
1538-7933